Form 4: Acrivon Therapeutics COO Sells Shares

Eric Devroe, Chief Operating Officer of Acrivon Therapeutics, Inc., reported a transaction involving the sale of common stock.

Summary

• Eric Devroe, Chief Operating Officer of Acrivon Therapeutics, Inc. (ACRV), reported a transaction on May 14, 2026.
• The transaction involved the withholding of 613 shares of common stock by the issuer to satisfy mandatory tax withholding requirements upon the vesting of restricted stock units.
• Following this transaction, Mr. Devroe beneficially owns 73,972 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the transaction appears to be a standard tax withholding event related to vested restricted stock units, not indicative of a change in management's outlook on the company's performance.

Negatives

• The Chief Operating Officer of Acrivon Therapeutics, Eric Devroe, disposed of 613 shares of common stock.

Future Outlook

No forward-looking statements or guidance were provided in this filing.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, providing transparency into executive stock activity. This specific filing indicates a routine tax-related withholding event rather than a strategic sale.

Stakeholder Impact

• Shareholders: The transaction involves a routine tax withholding, which is not expected to significantly impact the share price or indicate a change in management's confidence in the company.

Key Dates

Keywords

Form 4, SEC Filing, Acrivon Therapeutics, ACRV, Insider Transaction, Stock Sale, Restricted Stock Units, Tax Withholding, Chief Operating Officer